

DECIPHER BLADDER TURBT

DECIPHER BLADDER TURBT REQUISITION FORM
 Fax: 1.855.324.2768 (Toll-Free) or 1.858.408.7420 (Direct)
 Email: orders@deciphergene.com

BLUE HIGHLIGHTED AREAS ARE REQUIRED FIELDS

PATIENT INFORMATION

Patient Name			
DOB (MM/DD/YYYY)	Sex <input type="checkbox"/> M <input type="checkbox"/> F	Patient Medical Record #	Race / Ethnicity

ORDERING PHYSICIAN INFORMATION

Office / Practice / Institution Name	
Street Address / City / State / ZIP	
Telephone	Fax
Ordering Physician	NPI

DECIPHER TESTING

<input type="checkbox"/> Decipher Bladder TURBT <small>See reverse side for test description.</small>			
Specimen Type <input type="checkbox"/> TURBT (Only TURBT specimens are accepted for testing)	Date of TURBT Used for Radical Cystectomy Decision (MM/DD/YYYY)	Histology Type (Samples containing neuroendocrine tumors and adenocarcinomas are not accepted) <input type="checkbox"/> Urothelial/Transitional Cell Carcinoma <i>Select if present:</i> <input type="checkbox"/> Squamous Differentiation <input type="checkbox"/> Glandular Differentiation <input type="checkbox"/> Micropapillary <input type="checkbox"/> Other	
Lymph-Vascular Invasion <input type="checkbox"/> Not Identified <input type="checkbox"/> Present <input type="checkbox"/> Indeterminate <input type="checkbox"/> Not Reported	Evidence of Distant Metastasis <input type="checkbox"/> Yes <input type="checkbox"/> No	Tumor Type (check all that apply) <input type="checkbox"/> Muscle Invasive Carcinoma <input type="checkbox"/> Carcinoma In-Situ <input type="checkbox"/> Non-Muscle Invasive Carcinoma	Tumor Grade <input type="checkbox"/> Low Grade <input type="checkbox"/> High Grade
Prior radiation therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No		Prior chemotherapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	

PATHOLOGY / SPECIMEN INFORMATION. Complete if pathology report is not attached.

Laboratory	Specimen ID	Telephone	Fax
------------	-------------	-----------	-----

PHYSICIAN SIGNATURE

I confirm that this test is medically necessary and results will be used for treatment decisions and medical management for the patient. I hereby authorize testing and an informed consent has been obtained. I understand that, as part of the Decipher testing, additional genomic information will be collected as part of Decipher GRID and provided upon patient request as research use only (RUO) data.	
Ordering Physician Signature	Date (MM/DD/YYYY)

DECIPHER GRID

<input type="checkbox"/> Check here if the patient has requested a copy of their RUO data, i.e., GRID Tumor RNA Expression Profile. This can be requested at any time.
--

BILLING INFORMATION ***NOTE DECIPHER BLADDER IS NOT COVERED BY INSURANCE AND MUST BE PAID IN ADVANCE***

Name of Person Providing Payment <input type="checkbox"/> Patient <input type="checkbox"/> Other _____	Telephone Number	Email Address
---	------------------	---------------

THE FOLLOWING MUST BE ATTACHED

- Demographic / face sheet
- Pathology report

DECIPHER BLADDER TURBT TEST DESCRIPTION

Decipher® Bladder TURBT, a microarray gene expression assay, employs GenomeDx's proprietary Genomic Subtyping Classifier (GSC) to classify formalin-fixed paraffin-embedded (FFPE) bladder tumor samples into one of four molecular subtypes (Luminal, Luminal Infiltrated, Basal, Basal Claudin-Low) based on functional molecular pathways. The GSC was developed and validated in 305 neoadjuvant chemotherapy and 476 radical cystectomy alone patients from 10 cancer centers in North America and Europe. GSC uses RNA expression values to calculate multinomial probabilities of the tumor sample belonging to each of the four molecular subtypes. The higher the score, the more certain the sample will belong to assigned subtype. The patient tumor samples are classified as belonging to the subtype with the highest probability. The Decipher GSC molecular subtypes are based on a consensus classification derived from The Cancer Genome Atlas project and other previously published schema. The GSC has AUCs ranging from 0.85 to 0.97 for classifying a tumor sample into one of the four molecular subtypes in two independent validation cohorts (n=558). Results from Decipher Bladder are intended for use by the physician and patient as an adjunct to conventional clinical variables and models currently used for determining prognosis of patients diagnosed with muscle invasive bladder cancer using FFPE TURBT specimens.

DECIPHER GRID DESCRIPTION

The Decipher technology platform collects up to 1.4 million data points for each patient when the Decipher test is performed. Patients can access their genomic data at any time by requesting it from their ordering physician or contacting GenomeDx directly. The genomic data will be securely stored in the Decipher GRID database and will be de-identified prior to research use. For more information, please visit: www.genomedx.com

ORDER ACCEPTANCE CRITERIA

Orders submitted to GenomeDx for Decipher Bladder TURBT testing must meet the criteria below.

- Specimen Type: TURBT (Trans-Urethral Resection of Bladder Tumor)
- Tumor Type: Muscle Invasive Carcinoma
- Primary Histology Type: Urothelial/Transitional Cell Carcinoma
- No evidence of distant metastasis
- No prior neoadjuvant chemotherapy